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In recent times, an increasing number of assays have been developed and are available for diagnostic and clinical use (7) . Evaluation of such tests is important in order to assess not only their sensitivities and specificities compared to other more established commercial assays but also their clinical utility in detecting highrisk (HR) HPV genotypes and association to dysplastic or neoplastic changes in patients requiring treatment. Target amplification assays, such as Roche Amplicor (Amp) and Linear Array (LA), have a higher sensitivity for detection of high-grade lesion in the test-of-cure algorithm than the signal amplification-based assay, the Digene Hybrid Capture 2 (HC2) HPV test (3) .
In this study, the performance of the PapType HPV test in the detection of underlying CIN2 and CIN3 (Genera Biosystems Limited, Melbourne, Australia) was compared to those of the HC2 (using a threshold of 5,000 copies), AMP, and LA HPV assays. The PapType HPV test is a PCR-based qualitative in vitro diagnostic (IVD) test for the simultaneous detection and genotyping of 14 HR HPV genotypes and 2 low-risk (LR) HPV genotypes with an analytical sensitivity of 500 copies per reaction (PapType package insert). We utilized archival PreservCyt clinical specimens from a large cohort study aimed to evaluate the utility of HPV DNA in follow-up of women being treated for histologically proven highgrade dysplasia (3, 5) .
Stored frozen (unthawed) DNA previously extracted from PreservCyt samples using MagNA Pure LC (6) was tested using the PapType high-risk HPV detection and genotyping kit (Genera Biosystems Limited) according to the manufacturer's instructions and as described previously (8) . The Paptype HPV test was performed with 5 l of DNA in a final reaction volume of 20 l. All testing was performed blinded to the results of HC2, Amp, and LA. The PapType HPV test results were subsequently compared to those from histology, HC2, Amp, and LA HPV tests, which were performed and reported previously (3, 5) . Statistical analyses were performed using 2-by-2 contingency tables, with two-sided P values calculated using Fisher's exact test. Agreement between tests was assessed by Cohen's kappa statistic. Confidence intervals (95% CI) for proportions were calculated using a two-tailed test and assuming a random sample of the population. Confidence intervals for HPV genotypes detected were calculated by the Pearson test using a Poisson distribution.
Overall, 894 clinical specimens, comprising cytological scrapes with known contemporaneously collected histological results, were available for retesting with the PapType HPV test. Cytology clinical samples were obtained prior to treatment of patients. Overall, 10 specimens had negative internal controls and HPV and were removed from further analyses. Among the remaining 884 specimens, HR HPV positivity values determined by each of the four HPV tests were 73.0% (PapType), 65.6% (HC2), 75.5% (Amp), and 74.1% (LA). The levels of concordance between PapType and other HPV tests for the absence/presence of HR HPV types was considered good (HC2, 84.5% agreement, ϭ 0.638) to very good (Amp, 94.6% agreement, ϭ 0.858; LA, 95.9% agreement, ϭ 0.895) ( Table 1 ). Both HPV genotyping tests (PapType and LA) were compared for detection of 13 mutual HR HPV genotypes by the respective assays. Samples positive for HPV-33, -35, and -58 by LA were evaluated for the presence of HPV-52 by real-time PCR assay as described previously (4) . The PapType test identified 645 specimens as having HR genotypes (irrespective of LR HPV genotypes) (73.0%), 8 had only HPV-6 and/or -11 genotypes (0.9%), 16 had HPV-66 genotypes (1.8%), and 215 were HPV negative (24.3%), compared to LA with 655 specimens with HR genotypes (74.1%), 8 with only HPV-6 and/or -11 genotypes (0.9%), and 221 HPV negative/other types (including HPV-66) (25.0%) ( Table 1) .
When comparing the detection of HR HPV to histological diagnosis (using CIN2ϩ as a measure of clinically significant disease) ( (Table 2) . One limitation of this study was lack of consensus review of histology diagnosis, which may contribute to differences seen in detection of high grade. There was no significant difference in the number of each of the HPV genotypes detected by the PapType or LA HPV tests. However, PapType detected a higher number of HPV-33 infections and fewer HPV-51 infections. These differences were classified as not statistically significant (Fig. 1) .
This study demonstrated that 90.3% of women with a histological diagnosis of CIN2 or higher were positive for HR HPV by the PapType HPV test. This level of detection was comparable to both the LA (91.6%) and Amp HPV (92.4%) tests and greater than the HC2 HPV test (79.8%). Indeed, these 884 samples have previously been shown to contain HPV genotypes other than the 13 common HR genotypes in 131 (14.8%) samples (5) . This study showed lower sensitivities across the board for all the test compared to those reported earlier, as only a subset of those original samples were tested in this evaluation.
Individual HR HPV genotypes detected by the PapType HPV test matched those detected by the LA HPV test in 78.5% of cases, with a further 15.6% having a partial match. Among those samples testing HPV positive by one/both genotyping tests (n ϭ 690), 500 (72.5%) demonstrated identical HPV-type profiles, which is comparable with similar studies (1, 2, 9 ). Comparing samples positive for HPV-16 by either PapType or LA (n ϭ 321) showed 301 (93.8%) to be HPV-16 positive by both tests (as a single or multiple infection), with 12 being HPV-16 positive by LA and negative by PapType and 8 being HPV-16 negative by LA and positive by PapType.
As this study population focused on women with abnormal Pap smears, representing a population with inflated disease prevalence, the clinical performance shown here should not be extrapolated to the general screening population. However, this study provided the capacity to assess the PapType assay using samples from women with heightened levels of disease, providing a valuable cohort for sensitivity testing. This study demonstrates the ability of the PapType HPV test to accurately detect HR HPV in cervical samples. It shows a clinical sensitivity equivalent to LA and better than HC2 for the test-ofcure patient population studied.
